

Table 15: Summary of Demographic and Baseline Characteristics

Variable	Category/Statistic	Placebo (N=86)	Xanomeline Low Dose (N=96)	Xanomeline High Dose (N=72)	Total (N=254)
Pooled Age Group 1, n (%)	18-64	14 (16%)	8 (8%)	11 (15%)	33 (13%)
	>64	72 (84%)	88 (92%)	61 (85%)	221 (87%)
Gender, n (%)	Male	33 (38%)	41 (43%)	37 (51%)	111 (44%)
	Female	53 (62%)	55 (57%)	35 (49%)	143 (56%)
Age (years)	n	86	96	72	254
	Mean	75.2	76.0	73.8	75.1
	Median	76.0	78.0	75.5	77.0
	SD	8.59	8.11	7.94	8.25
	Min	52	51	56	51
	Max	89	88	88	89
Race, n (%)	AMERICAN INDIAN OR ALASKA NATIVE	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	BLACK OR AFRICAN AMERICAN	8 (9%)	6 (6%)	9 (12%)	23 (9%)
	WHITE	78 (91%)	90 (94%)	62 (86%)	230 (91%)
Ethnicity, n (%)	HISPANIC OR LATINO	3 (3%)	6 (6%)	3 (4%)	12 (5%)
	NOT HISPANIC OR LATINO	83 (97%)	90 (94%)	69 (96%)	242 (95%)

- 1.) Baseline is defined as the last non-missing value prior to the first dose.
- 2.) Treatment duration is calculated as: (last dose date - first dose date) + 28 days.
- 3.) Age is collected in years.

Table 15: Summary of Demographic and Baseline Characteristics

Variable	Category/Statistic	Placebo (N=86)	Xanomeline Low Dose (N=96)	Xanomeline High Dose (N=72)	Total (N=254)
Total Treatment Duration (Days)	n	85	95	72	252
	Mean	149.5	86.8	112.2	115.2
	Median	182.0	63.0	96.5	132.0
	SD	60.35	70.47	65.52	70.71
	Min	7	1	15	1
	Max	210	212	200	212

- 
- 1.) Baseline is defined as the last non-missing value prior to the first dose.
  - 2.) Treatment duration is calculated as: (last dose date - first dose date) + 28 days.
  - 3.) Age is collected in years.